BioCryst Pharmaceuticals Inc
XMUN:BO1
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
BioCryst Pharmaceuticals Inc
XMUN:BO1
|
US |
|
M
|
Medibank Private Ltd
XMUN:MPV
|
AU |
|
Persistent Systems Ltd
NSE:PERSISTENT
|
IN |
Intrinsic Value
The intrinsic value of 
BioCryst Pharmaceuticals Inc (BO1) under the Base Case is 12.533 EUR per share.
Compared with the current market price of 6.916 EUR, the stock appears
Undervalued by 45% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Cheap or expensive for this stock?
This block shows whether today’s valuation is cheap or expensive compared with the stock’s own history, and what happened after similar valuations in the past.
We compare the gap between the stock’s price and our estimated value over time.
- Undervalued can still be historically expensive. The stock may trade below our estimated value, but usually offer an even bigger discount.
- Overvalued can still be historically cheap. The stock may trade above our estimated value, but usually carry an even higher premium.
Market expectations can differ from our model, which may not fully capture everything affecting the price. That is why some stocks regularly trade above our estimated value and others below it.
The scale and chart show how today’s valuation compares with the past. The cards summarize past returns and waiting times until the stock stopped being cheap or expensive. This can happen because the price changed, our estimated value changed, or both.
Only completed periods are included. These are past results, not forecasts. The usual historical range does not necessarily mean fair value.
Fundamental Analysis
What BioCryst Pharmaceuticals Does
BioCryst Pharmaceuticals is a biotechnology company that makes medicines for rare diseases, with a strong focus on hereditary angioedema, a genetic condition that causes repeated swelling attacks. Its main marketed product is Orladeyo, an oral preventive treatment that patients take long term. The company also develops other drug candidates for rare immune and inflammatory disorders, but its business is built around selling specialty medicines rather than broad consumer health products.
- Headquarters
- United States of America US
- Employees
- 435
- IPO date
- Mar 4, 1994
Revenue & Expenses Breakdown
BioCryst Pharmaceuticals Inc
Earnings Waterfall
BioCryst Pharmaceuticals Inc
The intrinsic value for BioCryst Pharmaceuticals Inc (BO1) under the Base Case is 12.533 EUR.
Compared with the current market price of 6.916 EUR, the stock appears Undervalued by 45% .